Cartesian Therapeutics Announces New Employment Inducement Grant

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) announced an employment inducement grant for one new employee on Oct 2, 2025. The company issued an option for 9,700 shares with an exercise price of $10.34 (Nasdaq close on grant date). The option was approved by the board and granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement award.

The option vests 25% on Oct 2, 2026, then in three equal annual installments, becoming fully vested on Oct 2, 2029, and carries a 10-year term.

News Market Reaction

-1.45%

1 alert

-1.45% News Effect

On the day this news was published, RNAC declined 1.45%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On October 2, 2025, the Company issued to this employee an option to purchase an aggregate of 9,700 shares of the Company’s common stock with an exercise price of $10.34, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on October 2, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on October 2, 2029. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com

FAQ

What did Cartesian Therapeutics announce on Oct 3, 2025 regarding RNAC stock?

Cartesian announced an inducement option grant of 9,700 shares to one new employee, disclosed Oct 3, 2025.

What is the exercise price and grant date for the RNAC inducement option?

The option was granted on Oct 2, 2025 with an exercise price of $10.34 (closing price that day).

How does the RNAC option vest and when is it fully vested?

Vesting is 25% on Oct 2, 2026, then three equal annual installments; fully vested on Oct 2, 2029.

What is the term length of the RNAC inducement option?

The option carries a 10-year term from the grant date.

Under what Nasdaq rule was the Cartesian RNAC option granted?

The award was granted under Nasdaq Rule 5635(c)(4) as an inducement material to employment.

Will the RNAC inducement option immediately dilute existing shareholders?

The press release discloses the 9,700-share option grant but does not state outstanding shares or material dilution.